DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Clinical trials for DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT trials appear
Sign up with your email to follow new studies for DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Immune cells delivered directly to the brain show promise for kids with cancer
Disease control Recruiting nowThis early-stage study tests a new treatment for children and young adults (up to age 21) with certain brain tumors that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells, modified to target a protein called B7-H3 on tumor cell…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated May 26, 2026 03:40 UTC
-
New hope for kids with deadly brain tumors: adaptive trial tests drug combos
Disease control Recruiting nowThis study is for children and young adults with diffuse midline gliomas (DMGs), including DIPG, a rare and aggressive brain tumor. The trial tests whether combining the drug ONC201 with other new agents can help control the disease. About 360 participants will receive different …
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated May 26, 2026 03:38 UTC
-
New hope for deadly brain tumors: experimental combo targets DIPG
Disease control Recruiting nowThis study tests whether adding an experimental drug called VRT106 to standard radiation therapy can help control a rare, fast-growing brain tumor called diffuse midline glioma (including DIPG). About 10 adults aged 18 to 75 will receive the combination treatment. The main goal i…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE2 • Sponsor: Guangzhou Virotech Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 03:38 UTC
-
Experimental vaccine plus immunotherapy offers new hope for children with deadly brain tumors
Disease control Recruiting nowThis early-stage trial tests a new vaccine (rHSC-DIPGVax) combined with two immunotherapy drugs (BALSTILIMAB and ZALIFRELIMAB) in children with DIPG or diffuse midline glioma. The vaccine is designed to help the immune system recognize and attack tumor cells. The main goal is to …
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE1 • Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago • Aim: Disease control
Last updated May 26, 2026 03:37 UTC
-
Hope for kids with DIPG: major trial tests promising drug
Disease control Recruiting nowThis phase 3 trial tests whether the drug ONC201 works better than everolimus for children with diffuse intrinsic pontine glioma (DIPG), a rare and aggressive brain tumor. About 433 participants will receive one of the two drugs, and can switch if their disease gets worse. The go…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE3 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated May 26, 2026 03:35 UTC
-
New pill takes on brain tumors: first human trial begins
Disease control Recruiting nowThis early-phase study tests an oral drug called ONC206 in 102 adults with brain tumors that have come back or are rare. The main goal is to find the safest dose and understand side effects. Participants take the drug by mouth on a weekly schedule, and researchers monitor for any…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE1 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 03:34 UTC
-
Sound waves may help chemo reach deadly childhood brain tumors
Disease control Recruiting nowThis early-stage study tests whether focused ultrasound can safely open the blood-brain barrier in children with progressive diffuse midline glioma (DMG), a rare and aggressive brain tumor. The goal is to allow more of the chemotherapy drug etoposide to reach the tumor while redu…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE1 • Sponsor: Columbia University • Aim: Disease control
Last updated May 26, 2026 03:33 UTC
-
New hope for kids with aggressive brain tumors: targeted drug combo after radiation
Disease control Recruiting nowThis study tests whether adding two different drug combinations after radiation can help children and young adults with high-grade gliomas (including DIPG) live longer. One group receives ribociclib plus everolimus, and another receives ribociclib plus temozolomide, based on the …
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE2 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated May 26, 2026 02:48 UTC
-
Could two weeks of radiation be as good as six for this brain cancer?
Symptom relief Recruiting nowThis study is for people with a rare, aggressive brain tumor called diffuse midline glioma. Instead of the usual 6 weeks of daily radiation, researchers are testing a 2-week course. The goal is to see if the shorter treatment works just as well and helps patients feel better duri…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated May 26, 2026 03:33 UTC
-
Worldwide effort to unlock secrets of rare childhood brain cancer
Knowledge-focused Recruiting nowThis study creates a central registry and tissue bank for people of any age diagnosed with DIPG or DMG, rare and aggressive brain tumors. Researchers will collect medical information, scans, and tumor samples to study the biology of these cancers. The goal is to help scientists w…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Knowledge-focused
Last updated May 26, 2026 03:39 UTC
-
New brain tumor labels could change how doctors treat you
Knowledge-focused Recruiting nowThis study watches 1650 people with different types of brain tumors to see if the new 2021 classification system helps doctors choose better treatments. Researchers will track how long patients live and how well their tumors respond to therapy. The goal is to create clearer treat…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Knowledge-focused
Last updated May 26, 2026 03:28 UTC
-
Brain tumor DNA test could pave way for personalized treatment in kids
Knowledge-focused Recruiting nowThis study aims to analyze the genetic makeup of brain tumors in children, teens, and young adults (ages 1 to 39) newly diagnosed with high-grade glioma, including a type called DIPG. By identifying specific genetic changes in each tumor, researchers hope to match patients with m…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Sponsor: Nationwide Children's Hospital • Aim: Knowledge-focused
Last updated May 26, 2026 02:48 UTC